AINB, a leader in innovation in the field of antibody drug discovery based on artificial intelligence (AI), announced on the 19th that it participated in the NVIDIA GTC 2025 conference held in San Jose, California, USA from the 17th to the 21st and presented a poster containing its research results. AINB is a member of the NVIDIA Inception program and plans to showcase the excellence of its AI technology and research results at this event.
GTC 2025 is the world's largest AI and accelerated computing technology conference hosted by NVIDIA. It is an important event where CEO Jensen Huang's keynote speech and thousands of developers, innovators, and business leaders share the latest technology trends and success stories. In particular, it is an important event where discussions are held on AI and biohealth convergence technology.
AinB is changing the paradigm of the pharmaceutical and bio industries by utilizing its self-developed AI platform ALT-D to analyze massive biological data and quickly derive optimal antibody candidates. At this event, AinB will focus on the innovative impact of AI on the development of new antibody drugs through a technology presentation proving the excellence of its AI platform ALT-D and the results of joint research conducted with domestic and foreign pharmaceutical companies.
At this GTC 2025 presentation, we plan to present research results including AI-based new antibody discovery and validation of optimized antibodies through collaboration with GC Cell and Twist Bioscience. We expect to share real-world application cases and research results of AI-based antibody new drug discovery through poster presentations, and to actively network with various experts from academia and industry. Through this, we plan to seek opportunities for collaboration with global pharmaceutical companies and research institutes.
Eunyoung Park, CEO of AinB, said, “GTC 2025 is a place where cutting-edge technology companies and researchers from around the world gather to share innovative ideas and technologies, and it is a valuable opportunity to introduce our company’s AI antibody new drug discovery technology to the world.” She added, “We will use this event as an opportunity to present a new drug development paradigm in the field of AI and bio convergence.”
“As the development of new drugs using AI technology becomes more active, GC Cell expects that through joint research with AinB, it will be possible to more quickly and effectively explore new target binders applicable to CAR-T or CAR-NK cells,” said Won Seong-yong, CEO of GC Cell.
“Twist helps customers accelerate antibody discovery innovation by leveraging our DNA synthesis platform as well as antibody production and characterization technologies,” said Emily M. Leproust, Ph.D., Co-Founder and CEO of Twist Biosciences. “Our collaboration with AinB will further advance the antibody discovery process by combining our synthetic biology (SynBio) products and training datasets with AinB’s cutting-edge AI and ML technologies. We are excited to present our collaborative research findings at GTC 2025 and look forward to exploring new opportunities to drive the future of therapeutic antibody development.”
It is expected that AinB's participation in GTC 2025 will provide a new turning point for innovation in new drug development through the convergence of artificial intelligence and biotechnology, and is expected to contribute to technological innovation across the entire pharmaceutical industry in the future.
- See more related articles
You must be logged in to post a comment.